News | August 05, 2011

First Patient Enrolled in Trial of Peripheral Chronic Total Occlusion Device

August 5, 2011 — BridgePoint Medical Inc., a Minnesota-based medical device company, has enrolled its first patient in the Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions (PFAST-CTOs) study.

The company received approval from the U.S. Food and Drug Administration (FDA) in July 2011 to move forward with the United States-based investigational device exemption (IDE) for the peripheral devices and is now actively enrolling patients. The 10 center, 100 patient study is designed to assess the safety and effectiveness of the BridgePoint devices in chronically occluded arteries located in the lower extremities.

Subhash Banerjee, M.D., of the VA North Texas Health Care System and UT Southwestern Medical Center stated, "Predicated by the success of the BridgePoint coronary CTO system, we are very optimistic about the Peripheral device's performance possibilities and we are looking forward to a robust and successful study." Banerjee is the first physician to enroll a patient in the study.

The BridgePoint peripheral products are similar to the coronary system in concept, but have been specifically designed and adapted for use in peripheral vasculature and will expand the company's reach into the fast growing peripheral market.

Atherosclerotic peripheral artery disease (PAD) is a widely prevalent disorder that affects millions worldwide and is associated with significant morbidity and mortality. A CTO, which represents a complete artery blockage, typically cannot be treated with standard endovascular interventional devices and is often treated with surgery or medical therapy.

Patients with lower extremity CTOs often suffer from poor circulation in the legs, resulting in debilitating leg pain (claudication), limb threatening ischemia, and limb amputation. Various studies have estimated that chronic total occlusions are common and are found in approximately 50 percent of patients who undergo angiography.

For more information: www.bridgepointmedical.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init